Katie Laessig, MD

Katie Laessig, MD has an extensive work experience in the field of healthcare and pharmaceuticals.

Katie is currently serving as the Chief Medical and Regulatory Officer at Altesa BioSciences, Inc. since January 2023. Prior to this, they were a Scientific Advisory Board Member at Exavir Therapeutics and the Antimicrobial Resistance Action Fund in 2022. In 2021, they served as an Advisory Board Member at Vivpro Corp and as the Senior Vice President, Global Regulatory Affairs at Antios Therapeutics.

From 2018 to 2021, they held the position of Vice President, Therapeutic Strategy at IQVIA.

Before that, from 2015 to 2018, they served as the Senior Vice President, Regulatory Affairs and Medical Safety at RRD International, LLC, where they provided strategic regulatory and clinical development advice. Katie also worked at the FDA, where they served as the Deputy Division Director at the Division of Anti-Infective Products from 2007 to 2015 and as a Medical Team Leader and Medical Officer at the Division of Antiviral Products from 1999 to 2007.

Katie started their career as an Infectious Disease Specialist at Kaiser Permanente in 1997.

Katie Laessig, MD began their education journey by obtaining a High School Diploma from Bethesda Chevy Chase High School in 1984. Following this, they pursued their Bachelor of Arts (BA) degree in Biology-microbiology from Cornell University, which they completed in 1988. Later, they attended the University of Maryland School of Medicine from 1988 to 1992, earning their Medical Doctorate (MD) degree with a specialization in Medicine.

In addition to their formal education, Katie Laessig, MD has also achieved certification as a Board Certified in Infectious Diseases, granted by the American Board of Internal Medicine. However, the specific attainment dates for this certification are not provided.